Trio of biotechs raise funds to make enzymes and develop drugs for IBS and other autoimmune diseases
Huili Bio, a Hong Kong-based biotech, has reeled in “hundreds of million RMB,” which equates to at least $15 million, in a Series A financing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
